| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus
|
Szentpetery, Sylvia
|
|
|
21 |
4 |
p. 721-724
|
article
|
| 2 |
Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation
|
Oren, Yifat S.
|
|
|
21 |
4 |
p. 630-636
|
article
|
| 3 |
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant
|
Sawicki, Gregory S.
|
|
|
21 |
4 |
p. 675-683
|
article
|
| 4 |
Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation
|
Sanders, D.B.
|
|
|
21 |
4 |
p. 574-580
|
article
|
| 5 |
AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis
|
Kristensson, Cecilia
|
|
|
21 |
4 |
p. 684-690
|
article
|
| 6 |
CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis
|
Gould, Michelle J.
|
|
|
21 |
4 |
p. 600-602
|
article
|
| 7 |
CFTR modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis
|
Westhölter, Dirk
|
|
|
21 |
4 |
p. 713-720
|
article
|
| 8 |
C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response
|
VanDevanter, DR
|
|
|
21 |
4 |
p. 588-593
|
article
|
| 9 |
Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor
|
Collins, Bethany
|
|
|
21 |
4 |
p. 725-727
|
article
|
| 10 |
Duration of intravenous antibiotic treatment for acute exacerbations of cystic fibrosis: A systematic review
|
Nicholson, Trevor T
|
|
|
21 |
4 |
p. 562-573
|
article
|
| 11 |
Editorial Board
|
|
|
|
21 |
4 |
p. ii
|
article
|
| 12 |
Editorial – The ethical implications of treating a pregnant woman to benefit the fetus
|
Bennett, Rebecca
|
|
|
21 |
4 |
p. 558-559
|
article
|
| 13 |
Exploring provider attitudes and perspectives related to men's health in cystic fibrosis
|
Clarke, Alison R.
|
|
|
21 |
4 |
p. 652-656
|
article
|
| 14 |
Expression of cystic fibrosis lung disease modifier genes in human airway models
|
He, Gengming
|
|
|
21 |
4 |
p. 616-622
|
article
|
| 15 |
Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study
|
Carr, Siobhán B
|
|
|
21 |
4 |
p. e221-e231
|
article
|
| 16 |
Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations
|
Gold, Laura S.
|
|
|
21 |
4 |
p. 594-599
|
article
|
| 17 |
Idiopathic chronic pancreatitis treated with ivacaftor in a CFTR carrier with methylmalonic acidemia
|
Tang, Tin-Yun
|
|
|
21 |
4 |
p. 603-605
|
article
|
| 18 |
Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current understanding and gaps in knowledge
|
Lepissier, Agathe
|
|
|
21 |
4 |
p. 691-706
|
article
|
| 19 |
Interleukin-1 beta is a potential mediator of airway nitric oxide deficiency in cystic fibrosis
|
Nissen, Gyde
|
|
|
21 |
4 |
p. 623-625
|
article
|
| 20 |
Men's sexual and reproductive health in cystic fibrosis in the era of highly effective modulator therapies–A qualitative study
|
Clarke, Alison R.
|
|
|
21 |
4 |
p. 657-661
|
article
|
| 21 |
Modeling pulmonary cystic fibrosis in a human lung airway-on-a-chip
|
Plebani, Roberto
|
|
|
21 |
4 |
p. 606-615
|
article
|
| 22 |
Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro
|
Shaughnessy, Ciaran A.
|
|
|
21 |
4 |
p. 637-643
|
article
|
| 23 |
Neutrophil respiratory burst activity is not exaggerated in cystic fibrosis
|
Kelk, Dean
|
|
|
21 |
4 |
p. 707-712
|
article
|
| 24 |
News article
|
|
|
|
21 |
4 |
p. 553-555
|
article
|
| 25 |
Novel detection of specific bacterial quorum sensing molecules in saliva: Potential non-invasive biomarkers for pulmonary Pseudomonas aeruginosa in cystic fibrosis
|
Webb, Karmel
|
|
|
21 |
4 |
p. 626-629
|
article
|
| 26 |
Parenthood impacts short-term health outcomes in people with cystic fibrosis
|
Kazmerski, Traci M.
|
|
|
21 |
4 |
p. 662-668
|
article
|
| 27 |
Preferred health outcome states following treatment for pulmonary exacerbations of cystic fibrosis
|
McLeod, Charlie
|
|
|
21 |
4 |
p. 581-587
|
article
|
| 28 |
Priority areas in the assessment and treatment of CF exacerbations: Location, duration, inflammation
|
Carter, Suzanne C.
|
|
|
21 |
4 |
p. 556-557
|
article
|
| 29 |
Severity of the S1251N allele in cystic fibrosis is affected by the presence of the F508C variant in cis
|
Cuyx, Senne
|
|
|
21 |
4 |
p. 644-651
|
article
|
| 30 |
Survival in cystic fibrosis after acute respiratory failure supported by extracorporeal membrane oxygenation and/or invasive mechanical ventilation
|
Gibilaro, Jenna M.
|
|
|
21 |
4 |
p. 669-674
|
article
|
| 31 |
The impact of modulator therapies on pancreatic exocrine function: The good, the bad and the potentially ugly
|
Freeman, A. Jay
|
|
|
21 |
4 |
p. 560-561
|
article
|
Journal description